1d
MedPage Today on MSNAdd-On Metformin Promising in ER-Positive Endometrial CancerAdding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...
1d
MedPage Today on MSNMixed Results for Therapeutic Candidates for Platinum-Resistant Ovarian CancerPromising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...
The AstraZeneca PLC ADR AZN advanced 1.42% to $77.60 Friday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 2.61% to ...
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...
Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...
AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...
A cohort study of over 40,000 patients suggests that levels should be monitored for at least three months — longer than commonly practiced ...
New agents targeting endocrine therapy and CDK4/6 resistance in hormone receptor–positive breast cancer are in development.
Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...
The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results